Analyst Upgrades: Ariad Pharma, Cytokinetics, GrubHub

Analysts issued bullish notes on Ariad Pharmaceuticals, Inc. (ARIA), Cytokinetics, Inc. (CYTK), and GrubHub Inc (GRUB)

Dec 31, 2014 at 9:25 AM
facebook twitter linkedin


Analysts are upwardly revising their ratings today on oncology specialist Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), biopharmaceutical firm Cytokinetics, Inc. (NASDAQ:CYTK), and mobile carry-out platform GrubHub Inc (NYSE:GRUB). Here's a quick look at today's bullish brokerage notes on ARIA, CYTK, and GRUB.

  • Late Tuesday, JMP Securities raised its price target on ARIA to $8 from $7, and reiterated its "outperform" rating. The new target implies expected upside of 17.3% from yesterday's close at $6.82 -- which, for the record, means Ariad Pharmaceuticals, Inc. finished Tuesday completely flat for 2014. Despite the stock's lack of progress this calendar year -- and a recent downgrade from Credit Suisse -- most analysts remain in ARIA's corner. The stock sports 60% "strong buy" ratings from brokerage firms, with not a single "sell" to be found.

  • CYTK has jumped more than 7% in pre-market trading, aided by a price-target hike to $18 from $13 at Roth Capital. The brokerage firm apparently expects Cytokinetics, Inc. shares to gain nearly 161% from Tuesday's close at $6.90, though the stock has added just 6.2% over the last 12 months. In fact, CYTK only made its way into positive year-to-date territory on Monday, as traders cheered reports of an investment from Japanese firm Astellas Pharma. During the short term, a rush to cover by some of the weaker bearish hands could help CYTK extend its recent rally. The stock's short-interest ratio stands at 5.3, indicating more than a week's worth of pent-up buying pressure, at CTYK's average daily trading volume.

  • After yesterday's close, Barrington Research upgraded GRUB to "outperform" from "market perform," with a $43 price target -- roughly 20% north of the stock's Tuesday finish at $35.87. GrubHub Inc is up more than 3% ahead of the bell, which should help the shares extend a slim lead over resistance at their 80-day moving average (currently located at $35.72). While GRUB has floundered in recent months, and is now trading below its April 4 debut price of $40, the stock still has plenty of support from the brokerage community. Eight out of 10 analysts call GRUB a "buy" or better, and the average 12-month price target of $45.44 is less than 1 point south of the stock's Aug. 13 all-time high at $45.80.
 

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!